For years, the conversation around ADHD medication has been almost entirely one-directional: start it, optimize it, stay on it. Nobody had a clinical playbook for the other direction.

That just changed. The American Society of Clinical Psychopharmacology task force consensus statement on deprescribing stimulants in adults with ADHD was published May 20, 2026 in European Neuropsychopharmacology. Forty-five international psychopharmacology experts. First-ever clinical guidance on when and how to stop. Three formal categories that finally put structure around a question most prescribers have been answering with instinct alone.

The question “should I stop my ADHD meds?” has existed since the first prescription was written. Before this month, the clinical answer was effectively: ask your doctor, who also had no consensus guidance to draw from.

TL;DR

What this is	First-ever clinical consensus on stopping ADHD stimulants — 45-expert ASCP task force
Published	May 20, 2026 — European Neuropsychopharmacology
Three stopping categories	Inadequate efficacy, associated harm, misuse
What “deprescribing” means	Planned, supervised reduction — not quitting cold turkey
Paired with	The Lancet dosage optimization study from two weeks earlier

Who this is for: Anyone on stimulants questioning whether they still should be, anyone who’s been told to “just stop if it bothers you,” and anyone whose prescriber seems uncertain about when medication should end.

What Is Deprescribing?

Deprescribing is the planned, supervised reduction or discontinuation of a medication when the risks outweigh the benefits for a specific patient. It’s not quitting cold turkey. It’s not self-managed. It’s a clinical act — with criteria, a process, and prescriber oversight — applied to situations where continuing medication no longer makes sense.

That definition matters because “stopping ADHD meds” carries a lot of informal weight. People stop all the time, for all kinds of reasons, without clinical structure. The ASCP consensus is trying to build that structure: formal criteria, a shared vocabulary between patients and prescribers, and a framework that treats stopping as a legitimate clinical decision rather than a treatment failure.

Why There Was No Guidance Before This

Deprescribing as a formal clinical discipline has grown significantly over the past decade — mostly for cardiovascular drugs, antidepressants, and opioids. For ADHD stimulants, it didn’t exist in any meaningful way.

The gap wasn’t accidental. ADHD medication research flows almost entirely toward one question: does it work? Response rates, symptom reduction, cognitive outcomes. The clinical incentive structure rewards approval and optimization, not exit criteria.

But a lot of people stop anyway. Without framework. Often abruptly. Sometimes because side effects nobody addressed made the medication untenable. Sometimes because the diagnosis feels shaky in retrospect. Sometimes because life changed — pregnancy, cardiovascular concerns, a comorbid condition getting worse.

According to Medscape’s coverage, the task force wasn’t trying to discourage stimulant use. They were building a shared clinical vocabulary for situations where stopping is the right call — so patients don’t have to figure it out alone, and prescribers don’t have to improvise.

The Three Clinical Categories for Stopping

What are the clinical criteria for deprescribing ADHD stimulants?

The ASCP consensus identifies three formal categories where deprescribing stimulant medications is clinically appropriate for adults with ADHD:

1. Inadequate efficacy — the medication isn’t providing meaningful benefit (due to misdiagnosis, tolerance, or failure to respond even at optimal doses)
2. Associated harm: the medication is worsening a comorbid condition, or producing side effects significant enough to outweigh its benefits
3. Misuse: the patient is taking more than prescribed or diverting the medication to others

Each category is distinct. And each one covers situations that are common, recognizable, and have historically been handled without formal guidance.

---

Inadequate efficacy covers three sub-situations worth separating out.

Misdiagnosis. ADHD is overdiagnosed enough that this is a real scenario. If someone was prescribed stimulants based on an ADHD diagnosis that doesn’t hold up — and the medication isn’t actually helping — that’s inadequate efficacy by definition.

Tolerance. A medication that worked at first and has progressively lost effect despite dose adjustment. Not “feels weaker today” — a sustained pattern.

No optimal response despite dose optimization. This one connects directly to the Lancet Psychiatry dose-effect meta-analysis published two weeks earlier. That study quantified dosage sweet spots for five common ADHD medications across age groups. Once you know the optimal dose range — and you’ve been there, and it’s still not working — inadequate efficacy becomes a legitimate clinical conclusion, not just a feeling.

---

Associated harm is the category most people landing here are probably thinking about.

Stimulants worsening a comorbid condition. Anxiety disorders, bipolar disorder, certain cardiac conditions, and other comorbidities co-occur with ADHD at elevated rates. Stimulants can worsen all of them. If treating the ADHD is actively making something else worse, that’s a real clinical conflict — and the consensus names it as a legitimate stopping trigger.

Unmanageable side effects. Not “annoying” but significant: sustained cardiovascular effects, severe appetite suppression affecting health, psychiatric side effects that have become their own problem. The consensus is saying that there’s a legitimate threshold here, and crossing it justifies stopping.

This category matters because it validates something that often gets handled informally. Patients stop because they feel terrible. Sometimes prescribers tell them to push through. The ASCP consensus says: there’s a clinical line, and when you’ve crossed it, stopping is the right call.

---

Misuse is different in character from the first two.

Dose exceeding — taking more than prescribed in ways that aren’t medically indicated. Stimulants are dopaminergic and can reinforce escalation patterns. Diversion — giving, selling, or sharing medication with someone for whom it wasn’t prescribed. This is both a clinical concern and a legal one.

This category matters for clinical practice because it names a situation where deprescribing is the appropriate response to a patient behavior — not just a pharmacological issue, but a management situation that requires a different kind of conversation.

The Paired Picture: Optimization and Exit Criteria

The timing is actually striking.

The Lancet Psychiatry dose-effect meta-analysis dropped May 14. Largest stimulant dosing study ever conducted — 113 trials, 25,000+ participants, quantified sweet spots for five medications. It created a clinical framework for optimizing stimulant use with more precision than intuition alone. (The full breakdown is here, plus the free ADORMA dosing tool.)

The ASCP deprescribing consensus dropped May 20. Six days later.

Together, these two papers cover the full clinical arc: how to find the right dose (Lancet) and when to conclude the medication isn’t the right tool (ASCP). That paired framework hasn’t existed before. Both questions have been live for decades. Both now have research-backed guidance behind them.

Mapping Your Situation to the Categories

Most people questioning whether to stop ADHD meds aren’t thinking in clinical terminology. They’re thinking: “I hate how I feel on this,” or “I don’t know if it’s even working anymore,” or “my anxiety has been through the roof since my dose went up.”

Here’s a rough translation:

“My meds never really worked, or stopped working” → Inadequate efficacy. The ADORMA tool can help clarify whether you’ve actually been at a therapeutic dose. Genuine non-response at an optimal dose is different from being undertreated — and they point to different next steps.

“My meds make something else worse” → Associated harm. Worth naming explicitly with your prescriber: not “can I tolerate this?” but “is this medication producing a harm that outweighs the benefit?” Those are different questions, and the second one has a clinical answer.

“I’m taking more than prescribed, or it’s become something other than treatment” → Misuse. This one requires a direct, honest conversation with a prescriber — not because you’ll get in trouble, but because the path forward here is clinically different and needs professional guidance.

What This Changes About the Conversation

The most practical thing this consensus does is give patients language.

Before this month, if you brought concerns about stopping to a prescriber, the response depended entirely on that prescriber’s individual clinical judgment and comfort with an improvised discussion. Some are great at it. Some avoid it entirely.

Now there’s a published framework. The question “can we talk about whether the associated harm criteria apply to my situation?” is different from “I’m thinking about stopping my meds.” The first one arrives with clinical structure attached.

That’s not the same as self-diagnosing into a stopping category. It’s bringing a framework to a conversation that previously had none — which changes what’s possible in that conversation.

What This Guidance Doesn’t Cover

A few important scope limits:

It’s specific to adults. Pediatric deprescribing has different considerations — developmental factors, school performance implications, different comorbidity patterns. The ASCP guidance doesn’t apply directly there.

It identifies when to stop, not a universal how. Tapering schedules depend on the specific medication, dose, duration of use, and individual factors. That part remains prescriber judgment. Don’t use this guidance as a DIY tapering protocol.

It covers stimulants only. Non-stimulants like atomoxetine and viloxazine have different pharmacology and different stopping considerations. The ASCP consensus doesn’t apply to them.

It doesn’t resolve the misdiagnosis question. Naming inadequate efficacy as a deprescribing criterion implicitly raises the question of how often initial diagnoses were wrong. The consensus doesn’t engage with that — it’s a separate clinical conversation.

Building the Tool Layer, Whatever Medication Status You’re In

Whether you’re optimizing, tapering, or working without medication, the executive function gaps are still real. Medication reduces the load; it doesn’t eliminate it.

The BMJ’s interactive ADHD treatment database confirmed that CBT and external tools produce meaningful benefit alongside medication — which means they also carry more load when medication is reduced or stopped. Task initiation support, external working memory, time anchoring, emotional regulation tools. These aren’t consolation prizes. They’re the layer that keeps you functional during transitions.

If you’re in the inadequate efficacy category and medication genuinely isn’t working, the tool layer matters more, not less. And if you’re actively managing a tapering schedule, the best pill reminder apps become directly useful — tracking dose timing and reductions precisely when “just remember” isn’t reliable.

The AI ADHD coaching apps are worth knowing about too, particularly if you’re stepping down. Structured prompting and daily check-ins cover similar ground to what CBT does for task engagement and planning — at lower friction and cost than weekly appointments.

On the medication options side: centanafadine, the first triple reuptake inhibitor (dopamine + norepinephrine + serotonin), has a July 24 FDA decision date. If stimulants sit in the “associated harm” category for you — specifically because of anxiety worsening or emotional dysregulation — that’s worth knowing about before concluding there are no other pharmacological options.

The Bottom Line

Before May 20, 2026, if you asked your prescriber “should I stop my medication?”, the honest answer was: I’ll use my clinical judgment, because there’s no formal guidance for this.

Now there is. Forty-five experts. Three categories. Peer-reviewed. The first clinical consensus on this question in the history of ADHD pharmacotherapy.

Our take: this was overdue. The absence of exit criteria has quietly made stopping feel like treatment failure — when it’s often the right clinical call.

It won’t resolve every individual case — clinical judgment still matters, your situation is still yours. But it changes the quality of the conversation. Patients can arrive with a framework instead of a vague discomfort. Prescribers have criteria to work from instead of improvising.

You’ve probably had the question. You can now bring something more structured to the answer.

---

The ASCP consensus statement on deprescribing stimulants in adult ADHD was published May 20, 2026 in European Neuropsychopharmacology by an international task force of 45 experts convened by the American Society of Clinical Psychopharmacology. Medscape coverage here. Never stop or reduce medication without consulting your prescriber.